NA-921 by Biomed Industries for Fragile X Syndrome: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NA-921 overview

NA-921 is under development for the treatment of Rett syndrome and fragile X syndrome. The drug candidate is administered through oral route in the form of capsule.

Biomed Industries overview

Biomed Industries (Biomed) is a biotechnology company that offers alzheimers research, biotechnology, and medical research services. The company is headquartered in San Jose, California, the US.

For a complete picture of NA-921’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.